Results 71 to 80 of about 6,340 (200)

Update on Emerging Treatment Options for Primary Biliary Cholangitis

Hepatic Medicine: Evidence and Research, 2020
Maria T Aguilar,1 David M Chascsa2 1Department of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, AZ, USA; 2Department of Gastroenterology & Hepatology, Mayo Clinic, Phoenix, AZ, USACorrespondence: Maria T Aguilar Email aguilar.maria1 ...
Aguilar MT, Chascsa DM
doaj  

Diagnosis and Treatment of Primary Biliary Cholangitis

The Korean Journal of Gastroenterology, 2023
Primary biliary cholangitis (PBC) is an autoimmune disease prevalent in middle-aged women and characterized by chronic cholestasis. PBC is diagnosed when at least two of the following three criteria are met: elevated alkaline phosphatase, presence of PBC-
Kyung-Ah Kim
doaj   +1 more source

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

Hepatology Research, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver‐related ...
Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida   +44 more
wiley   +1 more source

Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment

BMC Gastroenterology
Background Ursodeoxycholic acid is the preferred first-line therapy for primary biliary cholangitis. Alternative therapies, such as obeticholic acid, are recommended for patients who cannot tolerate ursodeoxycholic acid or who have an inadequate response
Nicholas MacDonald, Rebecca Loh, Jonathan M. Fenkel, David A. Sass, Dina Halegoua-DeMarzio   +4 more
doaj   +1 more source

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases

Frontiers in Pharmacology, 2020
Cardiometabolic diseases are characterized as a combination of multiple risk factors for cardiovascular disease (CVD) and metabolic diseases including diabetes mellitus and dyslipidemia.
Chao Li, Jie Yang, Yu Wang, Yingzi Qi, Wenqing Yang, Yunlun Li, Yunlun Li   +6 more
doaj   +1 more source

Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. [PDF]

, 2019
The gut microbiome, the multispecies community of microbes that exists in the gastrointestinal tract, encodes several orders of magnitude more functional genes than the human genome. It also plays a pivotal role in human health, in part due to metabolism
Lynch, Susan V, Sharpton, Suzanne R, Terrault, Norah A, Yong, Germaine JM   +3 more
core   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies [PDF]

, 2019
Background: The heterogeneity of histological findings in preclinical diet-induced nonalcoholic fatty liver disease (NAFLD) animal models is highly challenging.
���������
core   +1 more source

Association Between Pruritus and Healthcare Utilization and Costs Among Individuals With Primary Biliary Cholangitis

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Background and Aims Pruritus is a debilitating, under‐prioritized symptom of primary biliary cholangitis (PBC). This study assessed its impact on healthcare resource utilization (HCRU) and costs in the US. Methods A retrospective cohort study of individuals with PBC was conducted using Komodo's claims and laboratory data between September 1 ...
Robert G. Gish, Michel H. Mendler, Edward A. Mena, Chong Kim, C. Fiorella Murillo Perez, Yi Pan, Lauren A. Do, Mihail Samnaliev, Maria Agapova   +8 more
wiley   +1 more source

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid

Therapeutics and Clinical Risk Management, 2017
Manan A Jhaveri, Kris V Kowdley Liver Care Network, Swedish Medical Center, Seattle, WA, USA Abstract: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease that predominantly affects women in early to middle age.
Jhaveri MA, Kowdley KV
doaj